Neuronetics Stock Performance
| STIM Stock | USD 3.66 0.17 4.44% |
The company secures a Beta (Market Risk) of 0.4, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Neuronetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neuronetics is expected to be smaller as well. At this point, Neuronetics has a negative expected return of -0.0492%. Please make sure to verify Neuronetics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Neuronetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neuronetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Neuronetics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (4.44) | Five Day Return 1.95 | Year To Date Return 145.64 | Ten Year Return (86.83) | All Time Return (86.83) |
1 | Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call | 04/22/2025 |
2 | Whats Driving Market Focus on This Medical Tech Firm in the sp 500 futures | 05/06/2025 |
3 | Disposition of 193460 shares by Furlong Stephen of Neuronetics at 4.27 subject to Rule 16b-3 | 05/12/2025 |
4 | Disposition of 6540 shares by Furlong Stephen of Neuronetics at 4.16 subject to Rule 16b-3 | 05/13/2025 |
5 | Insider Sell Stephen Furlong Sells 200,000 Shares of Neuronetics Inc | 05/15/2025 |
6 | Acquisition by Muir Glenn P of 30000 shares of Neuronetics subject to Rule 16b-3 | 05/22/2025 |
7 | Neuronetics reports annual meeting results - Investing.com | 05/28/2025 |
8 | Neuronetics to join Russell 3000 and Russell 2000 indexes | 06/02/2025 |
9 | Neuronetics Showcases Innovations in Mental Health Care STIM Stock News | 06/10/2025 |
10 | Neuronetics Appoints New Chief Financial Officer STIM Stock News | 07/15/2025 |
| Begin Period Cash Flow | 59.7 M | |
| Total Cashflows From Investing Activities | -2.4 M |
Neuronetics | Build AI portfolio with Neuronetics Stock |
Neuronetics Relative Risk vs. Return Landscape
If you would invest 388.00 in Neuronetics on April 20, 2025 and sell it today you would lose (22.00) from holding Neuronetics or give up 5.67% of portfolio value over 90 days. Neuronetics is currently does not generate positive expected returns and assumes 3.0289% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Neuronetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuronetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuronetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuronetics, and traders can use it to determine the average amount a Neuronetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0163
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | STIM |
Estimated Market Risk
| 3.03 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neuronetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuronetics by adding Neuronetics to a well-diversified portfolio.
Neuronetics Fundamentals Growth
Neuronetics Stock prices reflect investors' perceptions of the future prospects and financial health of Neuronetics, and Neuronetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuronetics Stock performance.
| Return On Equity | -1.44 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 309.38 M | ||||
| Shares Outstanding | 66.11 M | ||||
| Price To Book | 7.20 X | ||||
| Price To Sales | 2.71 X | ||||
| Revenue | 74.89 M | ||||
| Gross Profit | 57.41 M | ||||
| EBITDA | (34.56 M) | ||||
| Net Income | (43.73 M) | ||||
| Cash And Equivalents | 73.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 82.63 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 4.02 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (31 M) | ||||
| Earnings Per Share | (1.32) X | ||||
| Market Capitalization | 241.98 M | ||||
| Total Asset | 140.9 M | ||||
| Retained Earnings | (419.79 M) | ||||
| Working Capital | 26.86 M | ||||
About Neuronetics Performance
By examining Neuronetics' fundamental ratios, stakeholders can obtain critical insights into Neuronetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neuronetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 74.80 | 96.19 | |
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (1.58) | (1.50) |
Things to note about Neuronetics performance evaluation
Checking the ongoing alerts about Neuronetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuronetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuronetics generated a negative expected return over the last 90 days | |
| Neuronetics has high historical volatility and very poor performance | |
| Neuronetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 74.89 M. Net Loss for the year was (43.73 M) with profit before overhead, payroll, taxes, and interest of 57.41 M. | |
| Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Neuronetics Appoints New Chief Financial Officer STIM Stock News |
- Analyzing Neuronetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuronetics' stock is overvalued or undervalued compared to its peers.
- Examining Neuronetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuronetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuronetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuronetics' stock. These opinions can provide insight into Neuronetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share | Quarterly Revenue Growth 0.836 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.